NIAID considering funding smaller, intermediate trials to evaluate HIV vaccine candidates.

Executive Summary

NIAID CONSIDERING INTERMEDIATE TRIAL CONCEPT TO EVALUATE HIV VACCINE CANDIDATES in a smaller, less time-consuming fashion prior to moving them into Phase III, National Institute of Allergy & Infectious Diseases Division of AIDS Director Jack Killen, MD, said at the June 6 AIDS Research Advisory Committee meeting. The approach, termed the "intermediate trial," would consist of a "trial that's smaller, less costly and more manageable than a pivotal trial required for licensure of a vaccine," explained NIAID's Patricia Fast.